FeesSafety
Pluang+

Scribe Therapeutics shows CRISPR therapies lowering cholesterol and Lp(a) long-term in primates.

Market News
18 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Scribe Therapeutics shows CRISPR therapies lowering cholesterol and Lp(a) long-term in primates.

Scribe Therapeutics presented preclinical data demonstrating that its CRISPR-based therapies, STX-1150 and STX-1200, significantly reduce LDL cholesterol and lipoprotein(a) in non-human primates for extended periods. STX-1150 lowered LDL-C by over 50% for at least two years without permanent DNA changes, while STX-1200 achieved over 95% reduction in Lp(a) with a single dose. These findings highlight the potential for durable, one-time genetic treatments to manage cardiovascular risk factors more effectively than current lifelong therapies. Scribe plans to report initial human trial data for STX-1150 in early 2027.

Scribe Therapeutics' new genetic medicine data arrives as 86 of 150 Health-sector US stocks on Pluang fell today. For readers following health stocks, here is Pluang's market snapshot as of Nov 18, 2026 19:21 WIB: 55 stocks rose and 86 fell. Notable movers include FLNA at USD 0.47 with 97% sell orders, TNGX at USD 22.60 up 2.22%, and CTXR at USD 0.53 up 2.16% with 90% sell orders.

More News

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's reported adjusted earnings per share of $3.10, surpassing estimates of $2.88, and revenue of $22.80 billion, beating the $22.40 billion forecast. Comparable sales rose 1.8%, driven by strong online and professional services sales. The company ...

Company Fundamentals
Bullish
49 minutes ago
Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Daxor Corporation announced that a major Memphis health system has expanded its Blood Volume Analysis (BVA) program to an additional hospital outpatient site using Daxor’s ezBVA Lab service. This expansion allows the outpatient clinic to receive bloo...

Market News
Bullish
54 minutes ago
Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
1 hour ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
1 hour ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App